Symbols

CYTK

Cytokinetics·NASDAQ

--(--)

CYTK fundamentals

CYTK Q4 2025 Earnings

Cytokinetics (CYTK) released its earnings on Feb 24, 2026: revenue was 17.75M (YoY +4.89%), beat estimates; EPS was -1.5 (YoY -19.05%), beat estimates.

Revenue / YoY

17.75M

+4.89%

EPS / YoY

-1.5

-19.05%

Report date

Feb 24, 2026

CYTK Earnings Call Summary for Q4,2025

Myqorzo Milestones: FDA and EU approvals for obstructive HCM, with U.S. launch metrics showing 700+ REMS-certified HCPs and 90% prescribing intent.
ACACIA-HCM Trial: Co-primary endpoints (KCCQ and peak VO2) require statistical significance; results expected Q2 2026.
Financial Guidance: 2026 expenses of $830M-$870M, focused on Myqorzo launch and pipeline advancement.
HFpEF Expansion: Potential adjacency to nHCM based on shared pathophysiology and ACACIA outcomes.

Earnings

EPS

Revenue

Revenue & Expenses

CYTK has released its 2025 Q4 earnings report, with revenue of 17.75M, reflecting a YoY change of 4.89%, and net profit of -183.03M, showing a YoY change of -22.00%. The Sankey diagram below clearly presents CYTK's revenue sources and cost distribution.

Key Indicators

Cytokinetics (CYTK) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Cytokinetics (CYTK)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Cytokinetics (CYTK)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Cytokinetics (CYTK)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown